Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Ventyx Biosciences Announces Topline Results From Phase 2a Study Of VTX3232 In Early-Stage Parkinson's Disease; Says VTX3232 Resulted In Reductions In NLRP3-Related Biomarkers In CSF And Plasma

Author: Benzinga Newsdesk | June 17, 2025 06:08am

Posted In: VTYX